Various studies have shown the therapeutic benefits of NRF2 activators in infections with SARS-CoV-2 influenza, parainfluenza, and RSV (Table 7) [11,37,51,168,188,189,190,191,192,193]. The gene discussed is NFE2L2; the disease is infection.